Company intelligence / Profile preview

STAb Therapeutics

Madrid, Community of Madrid, Spainstabtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a next-generation cell immunotherapy platform where genetically engineered patient T cells secrete bispecific T-cell engagers in situ, redirecting both modified and unmodified bystander patient T cells to attack tumor-associated antigens. This approach aims to enhance immune redirection and persistence for the treatment of solid and hematological cancers. As of mid–2025, the company remains preclinical with no reported clinical trial results.

Therapeutic areas: OncologyHematology
Modalities: Cell therapy (engineered T cells)Bispecific antibodies (T cell engagers, TCEs)
Industry: Biotech

Drug pipeline

5 assets

STAb-TMM

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

CRIS Cancer Foundation [support/funding partner]

Beyond the preview

Go deeper on STAb Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STAb Therapeutics.

Explore the full profile